Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| P3 Health Partners Inc.PIII · Entity 4562 | Interim CFO, Senior VP & CAO | November 28, 2022 | November 30, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
P3 Health Partners Inc.
Report date November 28, 2022 · Filed November 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.62 · Expires 2032-11-28 | Direct | 100,000 |
Reported balance
After 2022-11-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-11-28 · Grant · Acquired 100,000 · Balance 100,000 F1: The option vests and becomes exercisable with respect to 25% of the shares on each of October 18, 2023, October 18, 2024, October 18, 2025 and October 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable with respect to 25% of the shares on each of October 18, 2023, October 18, 2024, October 18, 2025 and October 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 28, 2022 Filed Nov 30, 2022 21:05 UTC | P3 Health Partners Inc. PIII · Entity 4562 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $4.62 | $0.00 |
DisclosureSEC source: 0001104659-22-123232 · tm2231617-1_4seq1.xml · derivative · entry 1 Darakjian Erin · CIK 0001953468 · Interim CFO, Senior VP & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Class A Common Stock · 100,000 shares Expires 2032-11-28 F1 · derivative.exercise_date: The option vests and becomes exercisable with respect to 25% of the shares on each of October 18, 2023, October 18, 2024, October 18, 2025 and October 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.